Related Business Topics
Latest Headlines
BusinessWeek - Nov. 13, 2009, 10:12 AM
With the economy on the mend, cash-rich companies are ready to make deals again. But many targets, wary of lowball offers, aren't willing to sell. The latest standoff: Kraft Foods (KFT) vs. Cadbury (CBY). On Nov. 9 the U.S. packaged goods maker decided ...
BusinessWeek - Nov. 12, 2009, 3:20 PM
With the economy on the mend, cash-rich companies are ready to make deals again. But many targets, wary of lowball offers, aren't willing to sell. The latest standoff: Kraft Foods (KFT) vs. Cadbury (CBY). On Nov. 9 the U.S. packaged goods maker decided ...
BusinessWeek - Nov. 11, 2009, 9:29 PM
With the economy on the mend, cash-rich companies are ready to make deals again. But many targets, wary of lowball offers, aren't willing to sell. The latest standoff: Kraft Foods (KFT) vs. Cadbury (CBY). On Nov. 9 the U.S. packaged goods maker decided ...
Forbes.com - Nov. 11, 2009, 2:37 PM
, 04:08 PM EST Article SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) ...
Forbes.com - Nov. 5, 2009, 1:59 PM
SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its third quarter and nine months ended Sept. 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Revenue ...
Forbes.com - Oct. 19, 2009, 7:43 AM
Oct 19 (Reuters) - Facet Biotech Corp: * Facet Biotech's board of directors recommends stockholders continue to reject Biogen Idec * Biogen Idec has clearly failed to achieve meaningful support for its unsolicited tender offer' ...
Forbes.com - Oct. 19, 2009, 7:03 AM
SEATTLE (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Data from the open-label re-treatment phase of the Phase 2b study demonstrate that repeat administration with TRU-015 is generally well-tolerated and results in sustained ...
Forbes.com - Oct. 16, 2009, 3:06 PM
Oct 16 (Reuters) - Biogen Idec Inc: * Extends offer to acquire Facet Biotech Corp for ...
CNBC - Oct. 16, 2009, 3:05 PM
WASHINGTON - Biotech drugmaker Biogen Idec said Friday it has extended its tender offer for shares of Facet Biotech Corp., after the company's board unanimously rejected the hostile takeover bid. On Sept. 21, Biogen launched an unsolicited tender offer ...
Forbes.com - Oct. 16, 2009, 2:13 PM
BusinessWire - Biogen Idec Inc. (NASDAQ:BIIB) announced today that it has extended the tender offer by its wholly owned subsidiary, FBC Acquisition Corp., to purchase all of the outstanding shares of Facet Biotech Corporation (NASDAQ: FACT) to 12:00 ...
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
F
